Cancer patients get continued access to promising drug
NCT ID NCT02955940
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study offers ongoing treatment with ruxolitinib (alone or with other cancer therapy) to people with pancreatic, colorectal, breast, or lung cancer who were already benefiting from it in a previous Incyte study. It includes up to 10 participants and focuses on tracking side effects and safety. The goal is to keep providing the drug until it stops working or the patient can no longer take it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Instytut Hematologii I Transfuzjologii
Warsaw, 02-776, Poland
-
New York Oncology Hematology Pc.
Clifton Park, New York, 12065, United States
-
Renovatio Clinical Consultants Llc
The Woodlands, Texas, 77380, United States
-
Samodzielny Publiczny Szpital Kliniczny
Lublin, 20-081, Poland
-
Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii
Krakow, 31-501, Poland
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
UCLA Healthcare Hematology-Oncology
Santa Monica, California, 90404, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.